A Review of Strategies to Overcome Immune Resistance in the Treatment of Advanced Prostate Cancer

Overview

Journal Cancer Drug Resist

Date 2023 Oct 16

PMID 37842236

Authors

Kenneth Sooi

Robert Walsh

Nesaretnam Kumarakulasinghe

Alvin Wong

Natalie Ngoi

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has become integral in cancer therapeutics over the past two decades and is now part of standard-of-care treatment in multiple cancer types. While various biomarkers and pathway alterations such as dMMR and AR-V7 have been identified in advanced prostate cancer to predict immunotherapy responsiveness, the vast majority of prostate cancer remain intrinsically immune-resistant, as evidenced by low response rates to anti-PD(L)1 monotherapy. Since regulatory approval of the vaccine therapy sipuleucel-T in the biomarker-unselected population, there has not been much success with immunotherapy treatment in advanced prostate cancer. Researchers have looked at various strategies to overcome immune resistance, including the identification of more biomarkers and the combination of immunotherapy with existing effective prostate cancer treatments. On the horizon, novel drugs using bispecific T-cell engager (BiTE) and chimeric antigen receptors (CAR) technology are being explored and have shown promising early efficacy in this disease. Here we discuss the features of the tumour microenvironment that predispose to immune resistance and rational strategies to enhance antitumour responsiveness in advanced prostate cancer.

Citing Articles

Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.

Zeng H, Jiang Q, Zhang R, Zhuang Z, Wu J, Li Y Sci Rep. 2024; 14(1):22872.

PMID: 39358546 PMC: 11447205. DOI: 10.1038/s41598-024-74636-6.

Causal relationship between immune cells and prostate cancer: a Mendelian randomization study.

Ye Z, Deng X, Zhang J, Shao R, Song C, Zhao J Front Cell Dev Biol. 2024; 12:1381920.

PMID: 38566827 PMC: 10985200. DOI: 10.3389/fcell.2024.1381920.

References

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab J . Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother. 2018; 67(6):999-1009. PMC: 8697037. DOI: 10.1007/s00262-018-2131-2. View

Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S . Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018; 29(8):1807-1813. DOI: 10.1093/annonc/mdy232. View

Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M . CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. J Clin Med. 2020; 9(6). PMC: 7355670. DOI: 10.3390/jcm9061894. View

Beer T, Kwon E, Drake C, Fizazi K, Logothetis C, Gravis G . Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2016; 35(1):40-47. DOI: 10.1200/JCO.2016.69.1584. View

Simons J, Carducci M, Mikhak B, Lim M, Biedrzycki B, Borellini F . Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res. 2006; 12(11 Pt 1):3394-401. DOI: 10.1158/1078-0432.CCR-06-0145. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

10.

Lopez-Campos F, Gajate P, Romero-Laorden N, Zafra-Martin J, Juan M, Polo S . Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines. 2022; 10(3). PMC: 8945350. DOI: 10.3390/biomedicines10030537. View

11.

GuhaThakurta D, Sheikh N, Fan L, Kandadi H, Meagher T, Hall S . Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015; 21(16):3619-30. PMC: 4868054. DOI: 10.1158/1078-0432.CCR-14-2334. View

12.

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

13.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

14.

Aragon-Ching J, Williams K, Gulley J . Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007; 12:4957-71. DOI: 10.2741/2441. View

15.

Foster W, Car B, Shi H, Levesque P, Obermeier M, Gan J . Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2010; 71(5):480-8. DOI: 10.1002/pros.21263. View

16.

Narayan V, Barber-Rotenberg J, Jung I, Lacey S, Rech A, Davis M . PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022; 28(4):724-734. PMC: 10308799. DOI: 10.1038/s41591-022-01726-1. View

17.

Lemke G, Rothlin C . Immunobiology of the TAM receptors. Nat Rev Immunol. 2008; 8(5):327-36. PMC: 2856445. DOI: 10.1038/nri2303. View

18.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

19.

Antonarakis E, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C . Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2019; 38(5):395-405. PMC: 7186583. DOI: 10.1200/JCO.19.01638. View

20.

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View